Replies to post #311153 on Amarin Corp Plc (AMRN)

[HinduKush]

In California, at least a pharmacy switch to generic for any reason once the prescriber writes DAW (1) would be impossible to defend. Of course, the cost would be passed on to the patient--Therefore Amrn should come to the rescue to provide an out of a pocket plan for cash-pay customers and renegotiate with the PBM's of the private payors, to make a generic substitution financially worthless to the payors and their PBM's. An indigent plan with loose criteria would serve as a catch-all and a long-term 1-year contract at a great price NOW especially with big state medical plans and HMO's like Kaiser) would seal the deal against future generic switching for another year 2021, while Hikma chews the cud and awaits Teva case outcome and/or their API sourcing etc...all is far from lost with a careful strategy....
HK